2019

Announced the cessation of trading of our company's stock on the emerging stock market starting from November 8th, 2019.

Announced the acquisition of the U.S. patent certificate for our company's "RECOMBINANT PROTEIN" technology platform.

Announced that our sterile injection production line has received the official Good Manufacturing Practice (GMP) inspection report (EIR) from the U.S. FDA.

Announced that our innovative long-acting erythropoietin UB-852 has passed the review of the Taiwan Food and Drug Administration (TFDA) and has been granted approval to proceed with the Phase I human clinical trials.

Announced the acquisition of the patent certificate for our company's "Recombinant Protein" technology platform in the People's Republic of China.

Announced that our cream formulation production line has received the official inspection report (EIR) from the U.S. FDA.

Announced that our Hsinchu facility's cream formulation production line has received the official inspection report (EIR) from the U.S. FDA.

Announced the addition of a new dosage form (Freeze-Dried Injection) that has passed the Good Manufacturing Practice (GMP) inspection by the Ministry of Health and Welfare.

Announced receipt of the official inspection report (EIR) from the U.S. FDA.